Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04910932 Completed - Healthy Adults Clinical Trials

Effects of Breathing Exercises on Fear of COVID-19, Anxiety, Sleep and Quality of Life During the COVID-19 Pandemic

Start date: June 10, 2021
Phase: N/A
Study type: Interventional

It has been reported that in the first stages of the pandemic, a significant portion of the general population experienced psychological problems such as anxiety, depression and post-traumatic disorders. These problems persist today. A balanced diet, physical activity participation and relaxation techniques are recommended for preventing such problems. In studies conducted before the pandemic, it is reported that breathing exercises have positive effects on anxiety, sleep and quality of life in both patients and healthy individuals. Aim of this study is to investigate the effects of breathing exercises applied via teleconference on fear of COVID-19, anxiety, sleep and quality of life in healthy adult population.

NCT ID: NCT04910880 Completed - Covid19 Clinical Trials

Personal Protective Equipment Comfort and User Attitude During COVID-19

Start date: June 8, 2021
Phase:
Study type: Observational

There are studies in the literature that evaluate the attitude, behavior and comfort level of students who do internships in different disciplines (medicine, pharmacy) towards the use of protective equipment. However, no study evaluating physiotherapy and rehabilitation students was found. Therefore, the present study aims to investigate the behaviors and attitudes regarding the use of personal protective equipment of physiotherapy and rehabilitation department students who are interning in the Covid-19 pandemic.

NCT ID: NCT04910633 Completed - Cancer Clinical Trials

Medical Treatment of Solid Tumors at the Lyon University Hospital Cancer Institute During the First Wave of COVID-19 in France: A Conservative Approach

COCA
Start date: December 2, 2020
Phase:
Study type: Observational

An article to present how cancer patients were taken in charge at Lyon University Hospital Cancer Institute (France) during the first peak of the COVID-19 pandemic between March and May 2020 is under writing. It will present strategies that were set-up to avoid cross-contamination between patients and caregivers, patients treatment adaptation (timing, dosage,..) and how consultations, multidisciplinary team meetings, surgical procedures and clinical trials were impacted. Part of this article will also illustrate the characteristics of patients with a solid tumor(s) that have been hospitalized during this timeframe for the COVID-19. How cancer type and stage affect Covid severity and mortality.will be described for a small sample of patients (44). These qualitative figures will be compared to literature current state of the art.

NCT ID: NCT04910607 Completed - Obesity Clinical Trials

Social and Psychological Impacts of SARS-Cov-2 Pandemic Period in the Obese Population.

OBIMPACOV
Start date: January 21, 2022
Phase:
Study type: Observational

The population suffering from obesity is particularly at risk during this pandemic period. The Nouvelle Aquitaine region is not spared, since according to the regional epidemiological report of 7 May 2020, carried out by Santé Publique France, 39.2% of cases admitted to the intensive care unit in Nouvelle Aquitaine and presenting risk factors are overweight or obese. Other risk factors, such as social-environmental factors, must be taken into consideration. Socio-demographic surveys in this area highlight the socio-economic and territorial inequalities that interfere with obesity issues. Similarly, the issues of stigmatisation and isolation seem to be at the heart of the question of how to deal with these people.

NCT ID: NCT04910542 Recruiting - Covid19 Clinical Trials

Epidemiologic Intelligence Network (EpI-Net) to Promote COVID-19 Testing

EpI-Net
Start date: March 9, 2021
Phase: N/A
Study type: Interventional

The investigators propose a mixed-methods intervention design to evaluate the acceptability of epidemic intelligence (EpI-Net) intervention using Community Engagement (CE) principles to promote COVID-19 testing and prevention practices in socially vulnerable communities in PR. The team hypothesizes that the integration of lay community leaders, trained in the use of COVID-19 prevention technology tools (EpI-Net), will result in increased COVID-19 testing uptake and prevention practices among the targeted socially and epidemiologically vulnerable communities in Puerto Rico.

NCT ID: NCT04910360 Enrolling by invitation - COVID-19 Pneumonia Clinical Trials

Embolism in COVID-19 Positive Patients

Start date: March 5, 2021
Phase:
Study type: Observational

Covid-19 outbreak has caused death of millions of people because of not only the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection itself but also infection dependent complications. Abnormalities in thrombotic events leads to some of these complications which eventually result in emboli. The endothelial damage caused by the virus interacting with ACE2 on the host cells leads to the activation of coagulation cascade. Accumulation of byproducts of the cascade might have some roles in embolism inducing risk of organ damage, other life-threatening problems, and even death. To enlighten the factors triggering embolism, the investigators have focused on genetic changes such as polymorphisms and mutations in certain genes in DNA samples coming from intensive care unit (ICU) patients.

NCT ID: NCT04910334 Enrolling by invitation - Covid19 Clinical Trials

Long-term Cognitive and Functional Status After COVID-19 Treatment at Danish ICUs

Start date: October 1, 2020
Phase:
Study type: Observational

This study is a prospective observational cohort study of 6 and 12 months long-term outcome of Danish speaking patients with COVID-19.

NCT ID: NCT04910295 Completed - Cancer Clinical Trials

Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

Start date: March 26, 2021
Phase:
Study type: Observational

Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-cancer drugs. Side effects of vaccination and actual incidence of COVID-19 will be monitored.

NCT ID: NCT04910282 Recruiting - Covid19 Clinical Trials

Impact of COVID-19 on Quality of Life of Seniors With Eye Disease and Implementations to Improve Wellness

Start date: January 1, 2023
Phase:
Study type: Observational

The ophthalmology clientele is vulnerable in the context of the coronavirus disease 2019 (COVID-19) pandemic because of their age and comorbidities. Specifically, elderly patients aged 65 and above with glaucoma, age-related macular degeneration, or diabetic retinopathy require regular follow-ups and commonly suffer from additional comorbidities. Further, because of the proximity between the patient and health care personnel during ophthalmological examinations, the risk of infection during visits is significant. The delicate balance between the risk of exposure to COVID-19 and visual loss in delaying cases is a psychological stressor to both patients and clinicians. A cross-sectional study accumulating the data of 425 patients aged 65 and above with various eye diseases will be conducted. Participants will be presented with a set of online questionnaires designed to collect data on health-related quality of life (HRQOL), vision-related quality of life (VRQOL), depression symptoms, anxiety, sleep quality, community integration, and their experience with tele-consultations. This study can help quantify the collateral impact of the COVID-19 beyond the direct impact of the virus, to improve future quality of care guidelines on non-COVID-19 conditions, and to help plan patient prioritization once restrictions are eased.

NCT ID: NCT04910269 Recruiting - Covid19 Clinical Trials

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

OTAC
Start date: August 6, 2021
Phase: Phase 3
Study type: Interventional

The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acute respiratory syndrome - coronavirus 2 (SARS-CoV2) infection who do not require hospitalization. The primary endpoint of this double-blind randomized trial is a five-category ordinal outcome that assesses the participant's clinical status seven days after the infusion of hIVIG or placebo. 1. Asymptomatic and no limitations in usual activity due to COVID-19 2. Mild COVID-19 illness or minor limitations to usual activity 3. Moderate COVID-19 illness and with major limitations to usual activity 4. Severe COVID-19 or serious disease manifestation from COVID-19 5. Critical illness from COVID-19 or Death Two strata of participants will be identified for analysis purposes. Stratum 2 will be participants who receive direct-acting antivirals (DAAs) or other anti-SARS-CoV2 agents that are approved/available and recommended for use as part of standard of care (SOC), estimated to be about 20% of participants. Stratum 1 will be participants who do not receive this agents, estimated to be about 80% of participants.